Search Results - "Falques, M"

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks by Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.

“…Summary Background Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis. Objectives To…”
Get full text

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) by Thaci, D., Piaserico, S., Warren, R.B., Gupta, A.K., Cantrell, W., Draelos, Z., Foley, P., Igarashi, A., Langley, R.G., Asahina, A., Young, M., Falqués, M., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Reich, K.

“…Summary Background The phase III reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti‐interleukin‐23p19 monoclonal antibody tildrakizumab…”
Get full text

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial by Piraccini, B.M., Blume‐Peytavi, U., Scarci, F., Jansat, J.M., Falqués, M., Otero, R., Tamarit, M.L., Galván, J., Tebbs, V., Massana, E.

“…Background Oral finasteride is a well‐established treatment for men with androgenetic alopecia (AGA), but long‐term therapy is not always acceptable to…”
Get full text

Use of reflectance confocal microscopy to evaluate 5‐fluorouracil 0.5%/salicylic acid 10% in the field‐directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double‐blind, vehicle‐controlled trial by Ulrich, M., Reinhold, U., Falqués, M., Rodriguez Azeredo, R., Stockfleth, E.

“…Background Actinic keratosis (AK) is a common skin disorder that can progress to invasive squamous‐cell carcinoma. AK can present as clinical (visible) or…”
Get full text

Randomised clinical trials: linaclotide phase 3 studies in IBS‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints by Quigley, E. M. M., Tack, J., Chey, W. D., Rao, S. S., Fortea, J., Falques, M., Diaz, C., Shiff, S. J., Currie, M. G., Johnston, J. M.

“…Summary Background Treatment options that improve overall symptoms of irritable bowel syndrome with constipation (IBS‐C) are lacking. Aim A prespecified…”
Get full text

Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan by Goadsby, P J, Zanchin, G, Geraud, G, de Klippel, N, Diaz-Insa, S, Gobel, H, Cunha, L, Ivanoff, N, Falques, M, Fortea, J

“…The study was designed to compare the response to almotriptan in migraine patients who take medication early in the course of the attack with that when…”
Get more information

Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study by Kerkhof, P.C.M., Loewe, R., Mrowietz, U., Falques, M., Pau‐Charles, I., Szepietowski, J.C.

“…Background Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment. BRIDGE was a randomized, double‐blind, phase III…”
Get full text

Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD by Magnussen, H, Watz, H, Zimmermann, I, Macht, S, Greguletz, R, Falques, M, Jarreta, D, Garcia Gil, E

“…Summary The Genuair® inhaler is a new multidose dry powder inhaler for the delivery of aclidinium bromide – a novel, long-acting, muscarinic antagonist in…”
Get full text

The Impact of Allodynia on the Efficacy of Almotriptan When Given Early in Migraine: Data From the "Act When Mild" Study by Díaz-Insa, S., Goadsby, P. J., Zanchin, G., Fortea, J., Falqués, M., Vila, C.

“…ABSTRACT The objective of this study was to evaluate the impact of allodynia on treatment outcomes in the patients with acute migraine treated in the "Act when…”
Get full text

A study of the drug tildrakizumab in psoriasis patients by Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.

“…Summary Psoriasis is a common skin condition that causes red and scaly patches of skin. About 2% of people worldwide suffer from psoriasis. The authors of this…”
Get full text

Cost-Effectiveness of Linaclotide Compared to Antidepressants in the Treatment of Irritable Bowel Syndrome with Constipation in Scotland by Fisher, M, Falqués, M, Rance, M, Taylor, D.C.A, Lindner, L

Get full text

一项在银屑病患者中开展的 tildrakizumab 药物研究 by Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.

“…Summary 银屑病是一种常见的皮肤病,可导致皮肤发红和鳞斑。全世界约 2% 的人患有银屑病。该研究的作者希望了解 tildrakizumab 药物治疗银屑病的效果以及长期使用可能产生的副作用。 为此,他们综合了来自两项临床试验(reSURFACE 1 和 reSURFACE…”
Get full text

Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis by Ratner, Paul, Falqués, Meritxell, Chuecos, Ferran, Esbrí, Ramon, Gispert, Juan, Peris, Francesc, Luria, Xavier, Rosales, María José

“…Few randomized studies have compared the efficacy of ebastine and loratadine in the symptomatic treatment of seasonal allergic rhinitis (SAR). A meta-analysis…”
Get more information

一项在银屑病患者中开展的 tildrakizumab 药物研究 by Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.

Get full text

PGI27 - Cost-Effectiveness of Linaclotide Compared to Antidepressants in the Treatment of Irritable Bowel Syndrome with Constipation in Scotland by Fisher, M., Falqués, M., Rance, M., Taylor, D.C.A., Lindner, L.

Get full text

Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD by Fuhr, Rainard, MD, PhD, Magnussen, Helgo, MD, Sarem, Kristina, MD, Llovera, Anna Ribera, PharmD, PhD, Kirsten, Anne-Marie, MD, Falqués, Meritxell, MS, Caracta, Cynthia F., MD, FCCP, Garcia Gil, Esther, MD

“…Background The efficacy and safety of aclidinium bromide bid, a novel, long-acting, muscarinic antagonist, was assessed in patients with moderate to severe…”
Get full text

Survival of patients with HIV-related tuberculosis. Study of mortality during the first 9 months of treatment by Falqués Casanovas, M, Langohr, K, Gómez Melis, G, García de Olalla Rizo, P, Jansà López del Vallado, J M, Caylà Buqueras, J A

“…Among the individuals with tuberculosis who are infected with HIV a high degree of lethality has been found to exist during the first few weeks following the…”
Get full text